SCHEMBL326305

SCHEMBL326305

O=C1c2ccccc2C(=O)N1Cc1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.85
NPSR1 Q6W5P4 1/20 0.72
F2 P00734 1/20 0.64
PLG P00747 1/20 0.64
ELANE P08246 1/20 0.64
CTSG P08311 1/20 0.64
CMA1 P23946 1/20 0.64
CTRC Q99895 1/20 0.64
KMT2A Q03164 4/20 0.64
HPGD P15428 3/20 0.64
MEN1 O00255 3/20 0.64
ALDH1A1 P00352 3/20 0.63
ALDH2 P05091 1/20 0.63
CHRM1 P11229 1/20 0.63
CES1 P23141 1/20 0.63
ALDH3A1 P30838 1/20 0.63
ADRA1D P25100 1/20 0.63
ADRA1A P35348 1/20 0.63
ADRA1B P35368 1/20 0.63
MAPT P10636 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30472950 1.00 CASP3 (0.85) CASP3NPSR1F2PLGELANE
SCHEMBL27840845 0.92 CASP3 (0.79) CASP3NPSR1F2PLGELANE
SCHEMBL13442853 0.92 CASP3 (1.00) CASP3NPSR1KMT2AHPGDMEN1
SCHEMBL2570317 0.92 CASP3 (0.73) CASP3NPSR1F2PLGELANE
SCHEMBL1691386 0.88 CASP3 (0.68) CASP3NPSR1KMT2AHPGDMEN1
SCHEMBL2258501 0.87 KMT2A (0.70) CASP3NPSR1KMT2AHPGDMEN1
SCHEMBL11167209 0.87 CASP3 (0.67) CASP3NPSR1KMT2AHPGDMEN1
SCHEMBL12431370 0.87 NPSR1 (0.73) CASP3NPSR1F2PLGELANE
SCHEMBL17029125 0.86 CASP3 (0.66) CASP3NPSR1KMT2AHPGDMEN1
SCHEMBL11083983 0.86 CASP3 (0.66) CASP3NPSR1F2PLGELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115872877-A Synthesis method of aminotetraethyleneglycol 南京安伦化工科技有限公司 2023-03-31 CN claimed
CN-112409237-B Preparation method of N-benzylphthalimide 内蒙古源宏精细化工有限公司 2021-11-19 CN claimed
CN-112409237-A Preparation method of N-benzylphthalimide 内蒙古源宏精细化工有限公司 2021-02-26 CN claimed
CN-109305968-B A kind of preparation method of stable isotope labeling 6-benzyladenine internal standard reagent 坛墨质检科技股份有限公司 2019-09-27 CN claimed
CN-109305968-A A kind of preparation method of stable isotope labeling 6-benzyladenine internal standard reagent 坛墨质检科技股份有限公司 2019-02-05 CN claimed
CN-109293554-A It is the method that one step of starting material constructs N- benzylphthalimide using imines 桂林理工大学 2019-02-01 CN claimed
US-9656927-B2 Process for the synthesis of carboxylic acid derivatives COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-05-23 US claimed
CN-106432047-A Synthesis method of astemizole drug intermediate N-(4-fluorobenzyl)phthalimide 厦门市凯尔利信息科技有限公司 2017-02-22 CN claimed
CN-106008229-A Synthesis method of astemizole drug intermediate p-fluorobenzylamine 成都切斯特科技有限公司 2016-10-12 CN claimed
US-20160272554-A1 PROCESS FOR THE SYNTHESIS OF CARBOXYLIC ACID DERIVATIVES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-09-22 US claimed
EP-1503754-A1 BETA-AGONIST COMPOUNDS COMPRISING NITRIC OXIDE DONOR GROUPS AND REACTIVE OXYGEN SPECIES SCAVENGER GROUPS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) 2005-02-09 EP claimed
WO-2004078720-A1 PROCESS FOR THE PREPARATION OF 1,1,3,3-TETRAALKYLISOINDOLINE STARTING FROM N-BENZYLPHTHALIMIDE POLIMERI EUROPA S.P.A. (IT) 2004-09-16 WO claimed
WO-2003088961-A1 BETA-AGONIST COMPOUNDS COMPRISING NITRIC OXIDE DONOR GROUPS AND REACTIVE OXYGEN SPECIES SCAVENGER GROUPS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2003-10-30 WO claimed
US-6326388-B1 ANTIINFLAMMATORY AGENTS CELGENE CORPORATION 2001-12-04 US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272554-A1 PROCESS FOR THE SYNTHESIS OF CARBOXYLIC ACID DERIVATIVES PCCA, CPS1, CS CASP3 2552/4885NPSR1 3069/4885F2 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.